What's new? Log in Free sign up

Immix Biopharma (IMMX) News and press releases

Company Profile

News

From Benzinga Pro

Immix Biopharma Expands U.S. Clinical Trial Sites For NEXICART-2 In Relapsed/Refractory AL Amyloidosis

Adding Cleveland Clinic, UC Davis, And Sutter Health; MSKCC Remains Lead Site, With Ex-U.S. Data Showing 92% Response Rate

HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $7 price target.

HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $7 price target.

Reported Earlier, Immix Biopharma Secures $8M Funding From California Institute For Regenerative Medicine For CAR-T NXC-201 Trial In AL Amyloidosis

Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us", "IMMX") (NASDAQ:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL

HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $7 Price Target

News, Price Target, Reiteration, Analyst Ratings

HC Wainwright & Co. analyst Robert Burns reiterates Immix Biopharma (NASDAQ:IMMX) with a Buy and maintains $7 price target.

Immix Biopharma Doses First Patient In U.S. AL Amyloidosis Trial With CAR-T NXC-201; Data From ex-US Clinical Trial Reported At ASGCT 2024 Showed A 92% Overall Response Rate

Biotech, News, General

Lead site Memorial Sloan Kettering Cancer Center (MSKCC)Timing of milestone in-line with mid-2024 guidanceData from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rateLOS ANGELES, July 08, 2024

Press releases

From Benzinga Pro

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

New Sites Expand Opportunities for Patient Access and Enrollment Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health Lead site Memorial Sloan Kettering Cancer Center (MSKCC) Data from

California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us", "IMMX") (NASDAQ:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL

Immix Biopharma Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Lead site Memorial Sloan Kettering Cancer Center (MSKCC)Timing of milestone in-line with mid-2024 guidanceData from ex-US clinical trial reported at ASGCT 2024 showed a 92% overall response rate LOS ANGELES, July 08,

Immix Biopharma to Present at the Stifel 2024 Cell Therapy Forum

LOS ANGELES, June 17, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today

RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships

News, Management, Press Releases

LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.